Can gastric cancer be prevented by Helicobacter pylori eradication?

Best Practice and Research: Clinical Gastroenterology

Volumn 20, Issue 4, 2006, Pages 709-719

  Malfertheiner, Peter ^a   Fry, Lucia C ^a   Mönkemüller, Klaus ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

atrophic gastritis; carcinogenesis; gastric cancer; gastric cancer prevention; Helicobacter pylori

Indexed keywords

ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; GASTROINTESTINAL AGENT;

ARTICLE; ATROPHIC GASTRITIS; BACTERIAL VIRULENCE; CANCER GROWTH; CANCER INCIDENCE; CANCER REGRESSION; CANCER RISK; CANCER SCREENING; CHRONIC GASTRITIS; CLINICAL TRIAL; ERADICATION THERAPY; GASTRODUODENAL ULCER; GASTROINTESTINAL DISEASE; GENETIC PREDISPOSITION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTESTINE METAPLASIA; MEDICAL DECISION MAKING; META ANALYSIS; PEPTIC ULCER; PRECANCER; RECURRENCE RISK; RISK ASSESSMENT; RISK REDUCTION; STOMACH CANCER; STOMACH CARCINOGENESIS; SYSTEMATIC REVIEW;

ANTI-BACTERIAL AGENTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 33748686347     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2006.04.005     Document Type: Article

References (60)

1. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori: infection with Helicobacter pylori. Monographs on the Evaluation of Carcinogenic Risks to Humans vol. 61 (1994), International Agency for Research on Cancer pp. 177-240
2. Ekström A.M., Held M., Hansson L.-E., et al. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterololgy 121 (2001) 784-791
3. Brenner H., Arndt V., Stegmaier C., et al. Is Helicobacter pylori infection a necessary condition for non-cardia gastric cancer?. Am J Epidemiol 159 3 (2004) 252-258
4. Forman D. Lessons from ongoing intervention studies. In: Hunt R.H., and Tytgat G.N.J. (Eds). Helicobacter pylori: Basic Mechanisms to Clinical Cure 1998 (1998), Kluwer Academic Publishers, Dordrecht, The Netherlands 354-361
5. El-Omar E.M., Carrington M., Chow W.H., et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404 (2000) 398-402
6. Tsugane S. Salt, salted food intake, and risk of gastric cancer: epidemiologic evidence. Cancer Sci 96 (2005) 1-6
7. Malfertheiner P., Sipponen P., Naumann M., et al. Lejondal H. pylori-Gastric Cancer Task Force. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol 100 (2005) 2100-2115
8. Churin Y., Al-Ghoul L., Kepp O., et al. Helicobacter pylori CagA protein targets the c-Met receptor and enhances the motogenic response. J Cell Biol 161 (2003) 249-255
9. Strowski M.Z., Cramer T., Schafer G., et al. Helicobacter pylori stimulates host vascular endothelial growth factor-a (vegf-A) gene expression via MEK/ERK-dependent activation of Sp1 and Sp3. FASEB J 18 1 (2004) 218-220
10. Amieva M.R., Vogelmann R., Covacci A., et al. Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA. Science 300 (2003) 1430-1434
11. Wallasch C., Crabtree J.E., Bevec D., et al. Helicobacter pylori-stimulated EGF receptor transactivation requires metalloprotease cleavage of HB-EGF. Biochem Biophys Res Commun 295 (2002) 695-701
12. Gupta R.A., Polk D.B., Krishna U., et al. Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappa B-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J Biol Chem 276 (2001) 31059-31066
13. Jüttner S., Cramer T., Wessler S., et al. Helicobacter pylori stimulates host cyclooxygenase-2 gene transcription: critical importance of MEK/ERK-dependent activation of USF1/-2 and CREB transcription factors. Cell Microbiol 5 (2003) 821-834
14. Farrell J., and Wang T.C. The biology of gastric cancer. In: Rustgi A.K., and Crawford J. (Eds). Gastrointestinal Cancers (2003), W.B. Saunders 299-320
15. Coyle W.J., Sedlack R.E., Nemec R., et al. Eradication of Helicobacter pylori normalizes elevated mucosal levels of epidermal growth factor and its receptor. Am J Gastroenterol 94 (1999) 2885-2889
16. Blot W.J. Preventing cancer by disrupting progression of precancerous lesions. J Natl Cancer Inst 92 (2000) 1868-1869
17. Ito M., Haruma K., Kamada T., et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther 16 8 (2002) 1449-1456
18. Fox J.G., Dangler C.A., Sager W., et al. Helicobacter mustelae-associated gastric adenocarcinoma in ferrets (Mustela putorius furo). Vet Pathol 34 (1997) 225-229
19. Watanabe T., Tada M., Nagai H., et al. Helicobacter pylori infection induces gastric cancer in Mongolian gerbils. Gastroenterology 115 (1998) 642-648
20. Hirayama F., Takagi S., Iwao E., et al. Development of poorly differentiated adenocarcinoma and carcinoid due to long-term Helicobacter pylori colonization in Mongolian gerbils. J Gastroenterol 34 (1999) 450-454
21. Tokieda M., Honda S., Fujioka T., et al. Effect of Helicobacter pylori infection on the N-methyl-N'-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in Mongolian gerbils. Carcinogenesis 20 (1999) 1261-1266
22. Fox J.G., Sheppard B.J., Dangler C.A., et al. Germ-line p53-targeted disruption inhibits helicobacter-induced premalignant lesions and invasive gastric carcinoma through down-regulation of Th1 pro-inflammatory responses. Cancer Res 62 (2002) 696-702
23. Shimizu N., Inada K., Tsukamoto T., et al. Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian gerbils. Cancer Res 60 (2000) 1512-1514
24. Nozaki K., Shimizu N., Ikehara Y., et al. Effect of early eradication on Helicobacter pylori-related gastric carcinogenesis in Mongolian gerbils. Cancer Sci 94 (2003) 235-239
25. Teh M., Tan K.B., Seet B.L., et al. Study of p53 immunostaining in the gastric epithelium of CagA-positive and CagA-negative Helicobacter pylori gastritis. Cancer 95 (2002) 499-505
26. Murakami K., Fujioka T., Kodama M., et al. Analysis of p53 mutations and Helicobacter pylori infection in human and animal models. J Gastroenterol 37 supplement 13 (2002) 1-5
27. Koh T.J., and Wang T.C. Tumors of the stomach. In: Feldman M., Friedman L.S., and Sleisenger M. (Eds). Sleisenger & Fordtran's Gastrointestinal & Liver Disease. 7th edn. (2002), WB Saunders Co. 829-855
28. Sung J.J., Leung W.K., Go M.Y., et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol 157 (2000) 729-735
29. Konturek P.C., Rembiasz K., Konturek S.J., et al. Gene expression of ornithine decarboxylase, cyclooxygenase-2, and gastrin in atrophic gastric mucosa infected with Helicobacter pylori before and after eradication therapy. Dig Dis Sci 48 (2003) 36-46
30. Machado J.C., Figueiredo C., Canedo P., et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 125 (2003) 364-371
31. Konturek S.J., Starzynska T., Konturek P.C., et al. Helicobacter pylori and CagA status, serum gastrin, interleukin-8 and gastric acid secretion in gastric cancer. Scand J Gastroenterol 37 (2002) 981
32. Nilsson C., Sillén A., Enroth H., et al. Correlation between Cag pathogenecity island status and Helicobacter pylori associated gastroduodenal disease. Infect Immun 71 (2003) 6573-6581
33. Pan Z.J., vander Hulst R.W.M., Feller M., et al. Equally high prevalence of infection with CagA-positive Helicobacter pylori in Chinese patients with peptic ulcer disease and those with chronic gastritis-associated dyspepsia. J Clin Microbiol 35 (1997) 1344-1347
34. Mitchell H.M., Hazell S.L., Li Y.Y., et al. Serological response to specific Helicobacter pylori antigens: antibody against CagA antigen is not predictive of gastric cancer in a developing country. Am J Gastroenterol 91 (1996) 1785-1788
35. Blaser M.J., and Berg D.E. Helicobacter pylori genetic diversity and risk of human disease. J Clin Invest 107 (2001) 767-773
36. Alm R.A., Ling L.S., Moir D.T., et al. Genombbic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 397 (1999) 176-180
37. Kuipers E.J. Quasispecies development of Helicobacter pylori observed in paired isolates obtained years apart in the same host. J Infect Dis 181 (2000) 273-282
38. Salama N., Guillemin K., McDaniel T.K., et al. A whole-genome microarray reveals genetic diversity among Helicobacter pylori strains. Proc Natl Acad Sci U S A 19 (2000) 14668-14673
39. Israel D.A., Salama N., Arnold C.N., et al. Helicobacter pylori strain specific differences in genetic content, identified by microarray, influence host inflammatory responses. J Clin Invest 107 (2001) 611-620
40. Figueiredo C., Machado J.C., Pharoah P., et al. Helicobacter pylori and interleukin 1 genotypoing: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 94 (2002) 1680-1687
41. Lehours P., Menard A., Dupouy S., et al. Evaluation of the association of nine Helicobacter pylori virulence factors with strains involved in low-grade gastric mucosa-associated lymphoid tissue lymphoma. Infect Immun 72 (2004) 880-888
42. Machado J.C., Pharoah P., Sousa S., et al. Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology 121 (2001) 823-829
43. El-Omar E.M., Rabkin C.S., Gammon M.D., et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 124 (2003) 1193-1201
44. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 49 (2001) 347-353
45. Malfertheiner P., Bayerdörffer E., Diete U., et al. The GU-MACH study: the effect of one-week omeprazole triple therapy on Helicobacter pylori infection. Eradication healing and relapse in patients with active gastric ulcer. Aliment Pharmacol Ther 14 (1999) 703-712
46. Malfertheiner P., Kirchener T., Kist M., et al. Helicobacter pylori eradication and gastric ulcer healing - comparison of three pantoprazole-based triple therapies. Aliment Pharmacol Ther 17 (2003) 1125-1135
47. Correa P., Fontham E.T.H., Bravo J.C., et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and Helicobacter pylori therapy. J Natl Cancer Inst 92 (2000) 1881-1888
48. Moayyedi P., Wason C., Peacock R., et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 5 (2000) 206-214
49. Kyzekova J., and Mour J. The effect of eradication therapy on histological changes in the gastric mucosa in patients with non-ulcer dyspepsia and Helicobacter pylori infection. Prospective randomized intervention study. Hepatogastroenterology 46 (1999) 2048-2056
50. Larkin C.J., Watson P., Sloan J.M., et al. Gastric corpus atrophy following eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 13 (2001) 377-382
51. Schenk B.E., Kuipers E.J., Nelis G.F., et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 46 (2000) 615-621
52. Leung W.K., and Sung J.J. Review article: intestinal metaplasia and cancer carcinogenesis. Aliment Pharmacol Ther 16 (2002) 1209-1216
53. Wong B.C., Lam S.K., Wong W.M., et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291 (2004) 187-194
54. Uemura N., Okamoto S., Yamamoto S., et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345 (2001) 784-789
55. Zhou L.Y., Lin S.R., Ding S.G., et al. The changing trends of the incidence of gastric cancer after Helicobacter pylori eradication in Shandong area. Chin J Dig Dis 6 (2005) 114-115
56. Uemura N., Mukai T., Okamoto S., et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 6 (1997) 639-642
57. Saito K., Arai K., Mori M., et al. Effect of Helicobacter pylori eradication on malignant transformation of gastric adenoma. Gastrointest Endosc 52 (2000) 27-32
58. Ley C., Mohar A., Guarner J., et al. Helicobacter pylori eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial. Cancer Epidemiol Biomarkers Prev 13 (2004) 4-10
59. Mera R., Fontham E.T., Bravo L.E., et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut 54 (2005) 1536-1540
60. Malfertheiner P., Megraud F., O'Morain C., et al., European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16 (2002) 167-180